Cargando…
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
PURPOSE: Limited knowledge is available on the incidence of febrile neutropenia (FN) in intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor (G-CSF) in these patients. We aimed to estimate the rate at which patients associated with intermediate risk (10–20%)...
Autores principales: | Leon Rapoport, Bernardo, Garcia-Morillo, Marcial, Font, Carme, Samoon, Zarka, Jabbar, Adnan Abdul, Kourie, Hampig Raphael, Kayumba, Aline, Esposito, Francis, Popescu, Razvan Andrei, García-Gómez, Jesus, Heyman, Liezl, Smit, Teresa, Krendyukov, Andriy, Mathieson, Nicola, Cooksley, Tim, Anderson, Ronald, Klastersky, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570161/ https://www.ncbi.nlm.nih.gov/pubmed/37828258 http://dx.doi.org/10.1007/s00520-023-08071-0 |
Ejemplares similares
-
Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study
por: Rapoport, Bernardo Leon, et al.
Publicado: (2018) -
Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper
por: Cooksley, Tim, et al.
Publicado: (2020) -
Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
por: Aapro, Matti S., et al.
Publicado: (2023) -
Structure of unliganded membrane-proximal domains FN4-FN5-FN6 of DCC
por: Finci, Lorenzo I., et al.
Publicado: (2017) -
Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
por: Rapoport, Bernardo L., et al.
Publicado: (2021)